Form 8-K

8-K — Verrica Pharmaceuticals Inc.

Accession: 0001193125-26-338273

Filed: 2026-08-06

Period: 2026-08-06

CIK: 0001660334

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — d13828d8k.htm (Primary)

EX-99.1 (d13828dex991.htm)

GRAPHIC (g13828g0806201534159.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d13828d8k.htm · Sequence: 1

8-K

false 0001660334 0001660334 2026-08-06 2026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2026

Verrica Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-38529

46-3137900

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

44 W. Gay St., Suite 400

West Chester, PA

19380

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (484) 453-3300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class

Trading

symbol

Name of each exchange

on which registered

Common Stock

VRCA

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On August 6, 2026, Verrica Pharmaceuticals Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and six months ended June 30, 2026, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Exhibit Description

99.1

Press Release, dated August 6, 2026

104

Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Verrica Pharmaceuticals Inc.

Date: August 6, 2026

/s/ John J. Kirby

John J. Kirby

Interim Chief Financial Officer

EX-99.1

Filename: d13828dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

– Company reports record demand for YCANTH® as dispensed applicator units

grew to 19,626 in

Q2 2026, up 28.3% over the previous quarter and 46.1% year-over-year –

– Topline data from global Phase 3 program studying common warts currently expected in

mid-2027 –

– The Company’s cash runway could extend into 2028 based on

its current operating plan and

assuming full availability of its new credit facility –

– Company reports total revenue of $5.9 million in Q2 2026, including U.S. YCANTH net product

revenue of $5.1 million, up 18.7% over the previous quarter and 12.3% year-over-year –

– Conference call scheduled for today, August 6, 2026, at 4:30 pm ET –

WEST CHESTER, PA – Aug 6, 2026 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq:

VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced financial results for the second quarter ended June 30, 2026.

“Demand for YCANTH continues to accelerate, with dispensed applicator units reaching 19,626 for the quarter, up approximately 28% sequentially and 46%

on a year-over-year basis, and representing our highest quarterly total since launch. We believe that our commercial strategy is working well and provides us with a growing confidence that YCANTH can become the standard of care for patients

suffering from molluscum,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica.

“In addition to our commercial

efforts, we also continue to make progress with our work to expand the label for YCANTH to include common warts, an indication that is more than three times the six million patients estimated to be suffering from molluscum. Topline data from our

global Phase 3 program is currently expected in mid-2027, as our studies are recruiting well. We continue to enroll patients in the first pivotal study, COVE-2, and

first patients in the U.S. and Japan were dosed in the second pivotal trial, COVE-3, during the quarter,” Dr. Rieger continued. “With respect to our basal cell carcinoma program, we remain

highly encouraged by the Phase 2 data for our novel oncolytic peptide, VP-315. At the Society for Investigative Dermatology Annual Meeting in May, VP-315 demonstrated a

potential ability to impact both treated lesions, as well as showing evidence of a meaningful abscopal effect in untreated lesions. Based on the unique and promising profile of this Phase 3-ready asset, we are

continuing our Phase 3 readiness activities.”

Dr. Rieger concluded, “Finally, our new credit facility for up to $27.5 million with an

entity controlled by Paul B. Manning, Verrica’s Chairman and largest shareholder, gives us access to additional non-dilutive capital to support YCANTH’s continued commercialization and advance our

ongoing Phase 3 common warts program. Based on our current operating plan, we believe the full $27.5 million that may be available under the facility could extend our cash runway into 2028. We believe this quarter’s progress across our

YCANTH business for molluscum and our pipeline programs, along with this extended cash runway, positions Verrica well to deliver long-term value for patients and shareholders.”

Conference Call and Webcast Information

The Company will

host a conference call on Thursday, August 6, 2026, at 4:30 pm, to discuss its second quarter 2026 financial results and provide a business update. To participate in the conference call, please utilize the following information:

Domestic Dial-In Number: Toll-Free: 1-800-225-9448

International Dial-In Number: 1-203-518-9708

Conference ID: VERRICA

Participants can use Guest dial-in #s above and be answered by an operator.

Webcast:

https://viavid.webcasts.com/starthere.jsp?ei=1766684&tp_key=a08a369194

The call will be broadcast live over the Web and can also be accessed on Verrica Pharmaceuticals’ website: www.verrica.com.

The conference call will also be available for replay for one month on the Company’s website in the Events Calendar of the Investors section.

Business Highlights and Recent Developments

YCANTH® (VP-102)

•

During the second quarter of 2026, YCANTH dispensed applicator units totaled 19,626, representing a

year-over-year increase of approximately 46% from the second quarter of 2025. On a sequential basis, YCANTH dispensed applicator units increased approximately 28% from the prior quarter.

•

On June 22, 2026, the Company announced that the first U.S. patient was dosed in the second pivotal clinical

trial (COVE-3) in its global Phase 3 program evaluating YCANTH® (VP-102) for the treatment of common warts

in the US and Japan. Based upon current projections, the Company expects to present topline data from the program in mid-2027.

VP-315

•

On May 5, 2026, the Company announced the presentation of Phase 2 clinical data highlighting the potential

abscopal effects of its novel oncolytic peptide, VP-315 (ruxotemitide), for the treatment of basal cell carcinoma (BCC) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting.

Corporate

•

On August 6, 2026, the Company announced that it has entered into a credit agreement (the

“Facility”) with an entity controlled by Paul B. Manning, Verrica’s Chairman and largest shareholder for up to $27.5 million.

•

On July 21, 2026, the Company announced an exclusive distribution, marketing and supply agreement with

Medomie Pharma Ltd., regarding commercial rights to YCANTH® for the treatment of molluscum contagiosum in Israel.

Financial Results

Second Quarter 2026 Financial

Results

•

Total revenue for the three months ended June 30, 2026, was $5.9 million compared to total revenue of

$12.7 million for the three months ended June 30, 2025.

•

U.S. YCANTH product revenue, net was $5.1 million for the quarter ended June 30, 2026, compared to net

product revenue of $4.5 million for the quarter ended June 30, 2025. The increase in product revenue, net, was primarily related to increased deliveries of YCANTH to our distribution partners.

•

License and collaboration revenue was $0.8 million for the quarter ended June 30, 2026, consisting

primarily of commercial supply for Torii’s YCANTH launch in Japan, compared to license and collaboration revenue from Torii of $8.2 million for the three months ended June 30, 2025, which included $8.0 million of one-time milestone revenue.

•

Costs of product revenue were $0.4 million for the quarter ended June 30, 2026, compared to

$0.3 million for the quarter ended June 30, 2025, consisting primarily of product costs related to the sale of YCANTH.

•

Selling, general and administrative expenses were $10.3 million for the quarter ended June 30, 2026,

compared to $8.9 million for the same period in 2025. Excluding the impact of stock-based compensation, the increase of $1.3 million was primarily due to increased commercial spend, related to the expansion of the sales force.

•

Research and development expenses were $6.0 million for the quarter ended June 30, 2026, compared to

$1.8 million for the same period in 2025. Excluding the impact of stock-based compensation, the increase of $4.1 million was primarily attributable to costs associated with the Phase 3 program for common warts. The expense for the Phase 3

common warts program did not impact Verrica’s cash balance, as the first $40 million of payments for this program will be made by Torii under the Company’s collaboration and license agreement.

•

Expense of $1.7 million was recognized during the quarter ended June 30, 2026, as an agreement in

principle was reached to settle legal proceedings related to a class action brought against the Company in 2022. The expense represents Verrica’s share of the settlement after the insurance recovery.

•

Interest income was $0.1 million for the quarter ended June 30, 2026, compared to $0.2 million for

the quarter ended June 30, 2025. The decrease in interest income was primarily due to lower cash balances.

•

Interest expense was $0.2 million for the quarter ended June 30, 2026, compared to $2.1 million

for the same period in 2025. The decrease of $2.0 million was related to the settlement and termination of the Company’s OrbiMed debt facility in November 2025.

•

For the quarter ended June 30, 2026, net loss was $13.2 million, or $0.62 per share, compared to a net

income of $0.2 million, or $0.02 per share, for the same period in 2025.

•

For the quarter ended June 30, 2026, non-GAAP net loss was

$10.2 million, or $0.48 per share, compared to a non-GAAP net income of $1.2 million, or $0.12 per share, for the same period in 2025.

Year-to-date Financial Results

•

Product revenue, net was $9.4 million for the six months ended June 30, 2026, compared to

$8.0 million for the six months ended June 30, 2025.

•

License and collaboration revenue was $1.5 million for the six months ended June 30, 2026, compared to

$8.2 million for the six months ended June 30, 2025. License and collaboration revenue for the six months ended June 30, 2026 consisted of supplies and development activity with Torii. License and collaboration revenue for the six

months ended June 30, 2025 consisted of a one-time $8.0 million milestone payment from Torii as well as supplies and development activity.

•

Costs of product revenue were $1.0 million for the six months ended June 30, 2026, compared to

$0.8 million for the six months ended June 30, 2025.

•

Selling, general and administrative expenses were $20.3 million in the six months ended June 30, 2026,

compared to $17.7 million for the same period in 2025. Excluding the impact of stock compensation, the increase of $2.6 million was primarily due to increased commercial spend related to the expansion of the sales force.

•

Research and development expenses were $9.9 million in the six months ended June 30, 2026, compared to

$4.1 million for the same period in 2025. Excluding the impact of stock compensation, the increase of $5.6 million was primarily due to increased costs related to the Program for common warts.

•

Expense of $1.7 million was recognized during the six months ended June 30, 2026, as an agreement in principle

was reached to settle legal proceedings related to a class action brought against the Company in 2022. The expense represents Verrica’s share of the settlement after the insurance recovery.

•

Interest income was $0.3 million for the six months ended June 30, 2026, compared to $0.6 million

for the same period in 2025. The decrease of $0.3 million was primarily due to a lower cash balance.

•

Interest expense was $0.3 million for the six months ended June 30, 2026, and $4.3 million for the

same period in 2025. The decrease of $4.0 million was related to the settlement of the OrbiMed Loan Facility and the termination of the OrbiMed Credit Agreement in November 2025.

•

For the six months ended June 30, 2026, net loss was $22.8 million, or $1.07 per share, compared to a

net loss of $9.5 million, or $1.01 per share, for the same period in 2025.

•

For the six months ended June 30, 2026, non-GAAP net loss was

$19.0 million, or $0.89 per share, compared to a non-GAAP net loss of $7.1 million, or $0.75 per share, for the same period in 2025.

Non-GAAP Financial Measures

In evaluating the operating performance of its business, Verrica’s management considers non-GAAP (loss) income

from operations, non-GAAP net (loss) income and non-GAAP net (loss) income per share. These non-GAAP financial measures exclude

stock-based compensation expense and non-cash interest expense that are required by GAAP. Verrica excludes non-cash stock-based compensation expense from these non-GAAP measures to facilitate comparison to peer companies who also provide similar non-GAAP disclosures and because it reflects how management internally manages the

business. In addition, Verrica excludes non-cash interest expense from these non-GAAP measures to facilitate an understanding of the effects of the debt service

obligations on the Company’s liquidity and comparisons to peer group companies who also provide similar non-GAAP disclosures and because it is reflective of how management internally manages the

business. Verrica also excludes certain other one-time expenses and impacts from change in fair value of derivative liability and legal settlement, net of insurance recovery.

Non-GAAP (loss) income from operations, non-GAAP net (loss) income and non-GAAP

net (loss) income per share should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Non-GAAP (loss) income from operations, non-GAAP net (loss) income and non-GAAP net (loss) income per share have been reconciled to the

nearest GAAP measure in the tables following the financial statements in this press release.

About

YCANTH® (VP-102)

YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a

single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by

the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of

YCANTH was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum. YCANTH is also approved for the treatment

of molluscum contagiosum in Japan and is being studied in a global phase 3 program in the US and Japan for the treatment of common warts.

Approximately

250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay just $25 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced

cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information.

About Verrica

Pharmaceuticals Inc.

Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases,

including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered

treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily

children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also

entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information,

visit www.verrica.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the

Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar

expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the commercialization of YCANTH, the clinical development and benefits of Verrica’s product candidates,

including YCANTH (VP-102) and VP-315, the development and regulatory plans for YCANTH, the timing of release of clinical data from the Phase 3 studies of YCANTH for

common warts, Verrica’s ability to borrow funds under the Facility, Verrica’s achievement of milestones set forth in the Facility, and the commercial performance of YCANTH in Israel. These statements involve risks and uncertainties that

could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, and other risks and

uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Report on Form 10-Q

for the quarter ended June 30, 2026 to be filed with the SEC on August 6, 2026 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information

available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

VERRICA PHARMACEUTICALS INC.

Selected Statements of Operations Data

(in thousands except share and per share data)

(unaudited)

Three Months Ended June 30,

2026

2025

Revenue

Product revenue, net

5,093

4,534

License and Collaboration revenue

769

8,168

Total revenue

5,862

12,702

Operating Expenses:

Cost of product revenue

435

340

Cost of collaboration revenue

443

154

Selling, general and administrative

10,349

8,852

Research and development

6,034

1,846

Legal settlement, net of insurance recovery

1,698

—

Total expenses

18,959

11,192

(Loss) income from operations

(13,097

)

1,510

Interest income

111

228

Interest expense

(164

)

(2,131

)

Change in fair value of derivative liability

—

598

Other expense

)

Net (loss) income

(13,153

)

204

Net (loss) income per share

Basic

(0.62

)

0.02

Weighted average common shares outstanding

Basic

21,305,025

9,488,055

Net (loss) income per share

Diluted

(0.62

)

0.02

Weighted average common shares outstanding

Diluted

21,305,025

9,490,600

VERRICA PHARMACEUTICALS INC.

Selected Statements of Operations Data

(in thousands except share and per share data)

(unaudited)

Six Months Ended June 30,

2026

2025

Revenue

Product revenue, net

9,383

7,956

License and Collaboration revenue

1,502

8,185

Total revenue

10,885

16,141

Operating Expenses:

Cost of product revenue

979

763

Cost of collaboration revenue

788

168

Selling, general and administrative

20,338

17,700

Research and development

9,894

4,130

Legal settlement, net of insurance recovery

1,698

—

Total expenses

33,697

22,761

Loss from operations

(22,812

)

(6,620

)

Interest income

312

565

Interest expense

(324

)

(4,334

)

Change in fair value of derivative liability

—

852

Other expense

(11

)

Net loss

(22,835

)

(9,538

)

Net loss per share

Basic and diluted

(1.07

)

(1.01

)

Weighted average common shares outstanding

Basic and diluted

21,305,025

9,485,907

VERRICA PHARMACEUTICALS INC.

Selected Balance Sheets Data

(in thousands)

(unaudited)

June 30,

2026

December 31,

2025

Cash

11,198

30,147

Accounts receivable

11,090

5,397

Deferred R&D services, current portion

2,718

1,958

Insurance recovery asset

2,302

—

Inventory

2,712

2,236

Prepaid expenses and other assets

2,619

2,801

Total current assets

32,639

42,539

Deferred R&D services, non-current portion

706

2,354

PP&E, Lease right-of-use asset, other

2,672

2,238

Total assets

36,017

47,131

Legal settlement liability

4,000

—

R&D funding liability

8,414

5,066

Other current and noncurrent liabilities

19,296

17,322

Total liabilities

31,710

22,388

Total stockholders’ equity

4,307

24,743

Total Liabilities & Stockholders’ Equity

36,017

47,131

VERRICA PHARMACEUTICALS INC.

Reconciliation of Non-GAAP Financial Measures (unaudited)

(in thousands, except share and per share data)

Three Months Ended June 30, 2026

Loss from

Operations

Net loss

Net loss per

share (basic

and diluted)

GAAP

(13,097

)

(13,153

)

(0.62

)

Non-GAAP Adjustments:

Stock-based compensation - Selling, General & Admin (a)

799

0.04

Stock-based compensation - Research & Development (a)

396

0.02

Stock-based compensation - Cost of Product (a)

0.00

Stock-based compensation - Cost of Collaboration (a)

0.00

Legal settlement, net of insurance recovery (b)

1,698

0.08

Adjusted

(10,186

)

(10,242

)

(0.48

)

Three Months Ended June 30, 2025

Income from

Operations

Net income

per share

GAAP

1,510

204

0.02

Non-GAAP Adjustments:

Stock-based compensation - Selling, General & Admin (a)

588

0.06

Stock-based compensation - Research & Development (a)

300

0.03

Derivative liability change in value (b)

—

(598

)

(0.06

)

Non-cash interest expense (b)

—

691

0.07

Adjusted

2,398

1,185

0.12

(a)

The effects of non-cash stock-based compensation are excluded because

of varying available valuation methodologies and subjective assumptions. Verrica believes this is a useful measure for investors because such exclusion facilitates comparison to peer companies who also provide similar

non-GAAP disclosures and is reflective of how management internally manages the business.

(b)

The effects of legal settlement, net of insurance recovery, change in derivative liability and non-cash interest expense are excluded because Verrica believes such exclusions facilitate comparisons to peer group companies and is reflective of how management internally manages the business. Verrica also

believes that the exclusion of non-cash interest expense facilitates an understanding of the effects of the debt service obligations on the Company’s liquidity.

VERRICA PHARMACEUTICALS INC.

Reconciliation of Non-GAAP Financial Measures (unaudited)

(in thousands, except share and per share data)

Six Months Ended June 30, 2026

Loss from

Operations

Net loss

Net loss per

share (basic

and diluted)

GAAP

(22,812

)

(22,835

)

(1.07

)

Non-GAAP Adjustments:

Stock-based compensation - Selling, General & Admin (a)

1,392

0.07

Stock-based compensation - Research & Development (a)

672

0.03

Stock-based compensation - Cost of Product (a)

0.00

Stock-based compensation - Cost of Collaboration (a)

0.00

Legal settlement, net of insurance recovery (b)

1,698

0.08

Adjusted

(19,004

)

(19,027

)

(0.89

)

Six Months Ended June 30, 2025

Loss from

Operations

Net loss

Net loss per

GAAP

(6,620

)

(9,538

)

(1.01

)

Non-GAAP Adjustments:

Stock-based compensation - Selling, General & Admin (a)

1,373

0.14

Stock-based compensation - Research & Development (a)

541

0.06

Derivative liability change in value (b)

—

(852

)

(0.09

)

Non-cash interest expense (b)

—

1,359

0.14

Adjusted

(4,706

)

(7,117

)

(0.75

)

(a)

The effects of non-cash stock-based compensation are excluded because

non-GAAP disclosures and is reflective of how management internally manages the business.

(b)

believes that the exclusion of non-cash interest expense facilitates an understanding of the effects of the debt service obligations on the Company’s liquidity.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John Kirby

Interim Chief Financial Officer

jkirby@verrica.com

Kevin Gardner

LifeSci Advisors

kgardner@lifesciadvisors.com

GRAPHIC

Filename: g13828g0806201534159.jpg · Sequence: 6

Binary file (4959 bytes)

Download g13828g0806201534159.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information

Aug. 06, 2026

Cover [Abstract]

Amendment Flag

false

Entity Central Index Key

0001660334

Document Type

8-K

Document Period End Date

Aug. 06, 2026

Entity Registrant Name

Verrica Pharmaceuticals Inc.

Entity Incorporation State Country Code

Entity File Number

001-38529

Entity Tax Identification Number

46-3137900

Entity Address, Address Line One

44 W. Gay St.

Entity Address, Address Line Two

Suite 400

Entity Address, City or Town

West Chester

Entity Address, State or Province

Entity Address, Postal Zip Code

19380

City Area Code

(484)

Local Phone Number

453-3300

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock

Trading Symbol

VRCA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration